Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure

J Card Fail. 2023 Jun;29(6):896-906. doi: 10.1016/j.cardfail.2022.12.011. Epub 2023 Jan 8.

Abstract

Background: We sought to determine whether circulating modifiers of endothelial function are associated with cardiac structure and clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF).

Methods: We measured 25 proteins related to endothelial function in 99 patients from the GUIDE-IT study. Protein levels were evaluated for association with echocardiographic parameters and the incidence of all-cause death and hospitalization for heart failure (HHF).

Results: Higher concentrations of angiopoietin 2 (ANGPT2), vascular endothelial growth factor receptor 1 (VEGFR1) and hepatocyte growth factor (HGF) were significantly associated with worse function and larger ventricular volumes. Over time, decreases in ANGPT2 and, to a lesser extent, VEGFR1 and HGF, were associated with improvements in cardiac size and function. Individuals with higher concentrations of ANGPT2, VEGFR1 or HGF had increased risks for a composite of death and HHF in the following year (HR 2.76 (95% CI 1.73-4.40) per 2-fold change in ANGPT2; HR 1.76 (95% CI 1.11-2.79) for VEGFR1; and HR 4.04 (95% CI 2.19-7.44) for HGF).

Conclusions: Proteins related to endothelial function associate with cardiac size, cardiac function and clinical outcomes in patients with HFrEF. These results support the concept that endothelial function may be an important contributor to the progression to and the recovery from HFrEF.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cause of Death
  • Chronic Disease
  • Heart Failure* / epidemiology
  • Humans
  • Risk Factors
  • Stroke Volume / physiology
  • Vascular Endothelial Growth Factor A
  • Ventricular Dysfunction, Left*
  • Ventricular Function, Left / physiology

Substances

  • angiokines
  • Vascular Endothelial Growth Factor A